MST1 and metabolic dysfunction-associated steatotic liver disease: MST1 activation has been implicated in dilated cardiomyopathy, cardiomyocyte death following ischaemic injury, and inhibition of cardiac growth.63,64 Experimental studies further suggest that MST1 knockdown reduces atherosclerotic plaque formation and improves metabolic health, including protection against non-alcoholic fatty liver disease.65,66 Our study provides evidence of a potentially causal effect of MST1 on BP, a link that has been little explored.